Mizuho Raises its Price Target on Humana (HUM)

Humana Inc. (NYSE:HUM) is one of the 7 Best Turnaround Stocks to Buy in 2026.

On June 8, 2026, Mizuho raised the firm’s price target on Humana Inc. (NYSE:HUM) to $390 from $335 and maintained an Outperform rating on the shares. The firm said the managed care sector is entering a “more stable and predictable” policy environment, with the magnitude and frequency of policy-related surprises likely to moderate from the elevated levels of the past three years. Mizuho said that the backdrop should allow investors to focus on company fundamentals, pricing recovery, and the sector’s embedded earnings power.

On June 3, 2026, Bernstein analyst Lance Wilkes raised the firm’s price target on Humana Inc. (NYSE:HUM) to $425 from $288 and maintained an Outperform rating on the shares. Wilkes said Humana offers attractive EPS upside, with CAGR EPS growth of around 50% driven by Medicare Advantage sector margin recovery beginning this year and Humana-specific Stars recovery in 2028/2029. On June 1, 2026, Humana reaffirmed its FY26 adjusted EPS guidance of “at least $9.00.”

On May 20, 2026, Deutsche Bank upgraded Humana Inc. (NYSE:HUM) to Buy from Hold with a price target of $441, up from $235. The firm cited a stabilizing managed care market and said it expects Humana’s Medicare star ratings to recover.

Earlier, Humana reported Q1 adjusted EPS of $10.31, compared with the consensus of $10.20. CEO Jim Rechtin said the company had a solid start to the year and continues to make progress on customer experience and care.

Humana Inc. (NYSE:HUM) provides medical and specialty insurance products in the United States through its Insurance and CenterWell segments.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.